Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
31722-0303-31 31722-0303 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 3, 2024 In Use
31722-0304-31 31722-0304 Decitabine Decitabine 50.0 mg/10mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 10, 2024 In Use
31722-0774-60 31722-0774 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 5, 2024 In Use
31722-0775-12 31722-0775 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 5, 2024 In Use
31722-0775-60 31722-0775 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral April 19, 2024 In Use
42291-0939-12 42291-0939 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral April 23, 2024 In Use
43547-0632-01 43547-0632 Pemetrexed Pemetrexed 100.0 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Intravenous July 1, 2024 In Use
68001-0615-36 68001-0615 MITOMYCIN MITOMYCIN 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous July 8, 2024 In Use
68001-0616-77 68001-0616 MITOMYCIN MITOMYCIN 20.0 mg/40mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous June 24, 2024 In Use
68001-0617-79 68001-0617 MITOMYCIN MITOMYCIN 40.0 mg/80mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous July 11, 2024 In Use
68001-0618-37 68001-0618 Decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 3, 2024 In Use
68083-0592-01 68083-0592 Eribulin mesylate Eribulin mesylate 0.5 mg/mL Chemotherapy Antimitotic Agent Furopyrans Intravenous April 5, 2024 In Use
70069-0820-01 70069-0820 HYDROXYUREA HYDROXYUREA 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral June 18, 2024 In Use
70748-0339-01 70748-0339 DOXORUBICIN HYDROCHLORIDE DOXORUBICIN HYDROCHLORIDE 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 1, 2024 In Use
70748-0340-01 70748-0340 DOXORUBICIN HYDROCHLORIDE DOXORUBICIN HYDROCHLORIDE 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 1, 2024 In Use
71288-0174-21 71288-0174 Dacarbazine Dacarbazine 200.0 mg/20mL Chemotherapy Alkylating Agent Purine Analog Intravenous April 22, 2024 In Use
72338-0200-01 72338-0200 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous June 19, 2018 In Use
75907-0191-02 75907-0191 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 20, 2024 In Use
72603-0320-01 72603-0320 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 11, 2024 In Use
72603-0420-01 72603-0420 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 11, 2024 In Use
75907-0112-11 75907-0112 Melphalan Hydrochloride Melphalan Hydrochloride 50.0 mg/10ml Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 26, 2024 In Use
75907-0189-35 75907-0189 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 20, 2024 In Use
75907-0190-07 75907-0190 cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 20, 2024 In Use
81298-3890-01 81298-3890 Eribulin Mesylate Eribulin Mesylate 0.5 mg/mL Chemotherapy Antimitotic Agent Furopyrans Intravenous July 22, 2024 In Use
82293-0014-10 82293-0014 Sunitinib Malate Sunitinib Malate 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral May 1, 2024 In Use
82293-0015-10 82293-0015 Sunitinib Malate Sunitinib Malate 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral May 1, 2024 In Use
82293-0016-10 82293-0016 Sunitinib Malate Sunitinib Malate 37.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral May 1, 2024 In Use
82293-0017-10 82293-0017 Sunitinib Malate Sunitinib Malate 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral May 1, 2024 In Use
82293-0022-10 82293-0022 Pazopanib hydrochloride Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral April 24, 2024 In Use
82804-0136-30 82804-0136 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug. 28, 2024 In Use
83703-0532-01 83703-0532 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
83703-0533-01 83703-0533 Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 15, 2022 In Use
83703-0562-01 83703-0562 PEMETREXED PEMETREXED 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog INTRAVENTRICULAR Aug. 18, 2022 In Use
83703-0561-01 83703-0561 PEMETREXED PEMETREXED 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Aug. 18, 2022 In Use
83774-0102-01 83774-0102 Azacitidine AZACITIDINE 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous March 14, 2024 In Use
83831-0101-02 83831-0101 Docetaxel DOCIVYX 20.0 mg/2mL Chemotherapy Antimitotic Agent Taxane Intravenous May 9, 2024 In Use
83831-0102-08 83831-0102 Docetaxel DOCIVYX 80.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous May 9, 2024 In Use
83831-0103-16 83831-0103 Docetaxel DOCIVYX 160.0 mg/16mL Chemotherapy Antimitotic Agent Taxane Intravenous May 9, 2024 In Use
83831-0116-01 83831-0116 Cyclophosphamide Cyclophosphamide 500.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug. 1, 2024 In Use
83831-0117-02 83831-0117 Cyclophosphamide Cyclophosphamide 1.0 g/2mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug. 1, 2024 In Use
83831-0118-04 83831-0118 Cyclophosphamide Cyclophosphamide 2.0 g/4mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug. 1, 2024 In Use
83858-0101-60 83858-0101 Dasatinib PHYRAGO 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83858-0102-60 83858-0102 Dasatinib PHYRAGO 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83858-0103-60 83858-0103 Dasatinib PHYRAGO 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83858-0104-30 83858-0104 Dasatinib PHYRAGO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83858-0105-30 83858-0105 Dasatinib PHYRAGO 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
83858-0106-30 83858-0106 Dasatinib PHYRAGO 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
73116-0225-28 73116-0225 Duvelisib COPIKTRA 25.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
73116-0225-56 73116-0225 Duvelisib COPIKTRA 25.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 28, 2018 In Use
00781-3491-94 00781-3491 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Aug. 21, 2024 In Use

Found 10,000 results in 6 milliseconds — Export these results